CONTENTS

        Chapters
  1. Research and Regulatory Approval
  2. Use of Injectables
  3. Effectiveness and Reversibility
  4. Side Effects and Complications
  5. More Evidence in the Cancer Debate
  6. Noncontraceptive Health Benefits
  7. Counseling Issues
  8. Communicating with the Public
  9. Maximizing Access and Quality

Published with this issue:

Published by the Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, 111 Market Place, Suite 310, Baltimore, Maryland 21202-4012, USA

Volume XXIII, Number 2 August 1995

Fewer Sickle-Cell Crises

Sickle-cell disease is caused by a defect in the structure of hemoglobin that leads to deformation of red blood cells into a sickle shape when deprived of oxygen. These cells block blood flow, causing painful sickle-cell crises. Sickle-cell disease is most common among blacks and causes at least 80,000 deaths worldwide every year (231).

Testosterone, progesterone, and progestins such as DMPA prevent sickle-cell crises, probably by stabilizing the membrane of red blood cells (139). In the only study of DMPA and sickle-cell disease, women using DMPA in a 2-year trial had significantly fewer crises than women given a placebo. Hematological tests found significant increases in total hemoglobin and red cell counts among DMPA users and significant decreases in the level of irreversibly sickled cells (65).


Previous | Next
Top of Page | Table of Contents


111 Market Place, Suite 310, Baltimore, MD 21202, USA
Phone: (410) 659.6300/Fax: (410) 659.6266/E-mail: Poprepts@jhuccp.org

Population Reports